← Back
Data updated: Mar 10, 2026
MAIA PHARMS INC
Infectious DiseaseDermatologyNeurology
MAIA PHARMS INC is a pharmaceutical company focused on Infectious Disease, Dermatology, Neurology. Key products include DAPTOMYCIN.
2017
Since
7
Drugs
-
Trials
36
Approved (2yr)
Key Drugs
Recent Activity
DAPTOMYCIN 2026-01-30
Labeling
DAPTOMYCIN 2026-01-26
Labeling
BORTEZOMIB 2026-01-06
BORTEZOMIB 2025-12-17
BACLOFEN 2025-11-21
Manufacturing (CMC)
DAPTOMYCIN 2025-08-08
Labeling
BACLOFEN 2025-06-03
Manufacturing (CMC)
BACLOFEN 2025-06-03
Manufacturing (CMC)
BORTEZOMIB 2025-06-02
LEVOTHYROXINE SODIUM 2025-05-01
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 20%
1 drugs
Dermatology 20%
1 drugs
Neurology 20%
1 drugs
Oncology 20%
1 drugs
Metabolic 20%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Eli Lilly big-pharma
Metabolic, Oncology, Neurology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology, Oncology, Metabolic
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Novo Nordisk big-pharma
Metabolic, Oncology, Infectious Disease, Neurology
Active (6)
Discontinued (0)
Company Info
- First Approval
- 2017-05-08
- Latest
- 2024-11-21
- Applications
- 10